I. M. Modlin, K. D. Lye, and M. Kidd, A 5-decade analysis of 13,715 carcinoid tumors, Cancer, vol.267, issue.4, pp.934-959, 2003.
DOI : 10.1002/cncr.11105

J. C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary et al., One Hundred Years After ???Carcinoid???: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States, Journal of Clinical Oncology, vol.26, issue.18, pp.3063-3072, 2008.
DOI : 10.1200/JCO.2007.15.4377

K. Oberg, U. Knigge, D. Kwekkeboom, and A. Perren, On behalf of the ESMO guidelines working Group neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.23, pp.124-130, 2012.

J. Y. Scoazec and A. Couvelard, Tumeurs neuroendocrines du tube digestif et du pancr??as??: ce que le pathologiste doit savoir et doit faire en 2014, Annales de Pathologie, vol.34, issue.1, pp.40-50, 2014.
DOI : 10.1016/j.annpat.2014.01.003

G. Rindi, G. Klöppel, H. Alhman, M. Caplin, A. Couvelard et al., TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system, ENETS): TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system, pp.395-401, 2006.
DOI : 10.1007/s00428-006-0250-1

G. Rindi, G. Klöppel, A. Couvelard, P. Komminoth, M. Körner et al., TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system, Virchows Archiv, vol.80, issue.Suppl 4, pp.757-762, 2006.
DOI : 10.1007/s00428-007-0452-1

A. Couvelard, L. Deschamps, P. Ravaud, G. Baron, A. Sauvanet et al., Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors, Modern Pathology, vol.5, issue.2, pp.273-281, 2009.
DOI : 10.1385/EP:15:4:275

C. Shi, R. S. Gonzalez, Z. Zhao, T. Koyama, T. C. Cornish et al., Liver Metastases of Small Intestine Neuroendocrine Tumors: Ki-67 Heterogeneity and World Health Organization Grade Discordance With Primary Tumors, American Journal of Clinical Pathology, vol.143, issue.3, pp.398-404, 2015.
DOI : 10.1309/AJCPQ55SKOCYFZHN

F. Grillo, M. Albertelli, M. P. Brisigotti, T. Borra, M. Boschetti et al., Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor, Neuroendocrinology, vol.103, issue.5, 2015.
DOI : 10.1159/000439434

K. Lowe, A. Khithani, E. Liu, T. Winston, D. Christian et al., Ki-67 labeling: A more sensitive indicator of malignant phenotype than mitotic count or tumor size?, Journal of Surgical Oncology, vol.23, issue.6, pp.724-727, 2012.
DOI : 10.1002/jso.23124

M. S. Khan, T. V. Luong, J. Watkins, C. Toumpanakis, M. E. Caplin et al., A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms, British Journal of Cancer, vol.115, issue.9, pp.1838-1845, 2013.
DOI : 10.1200/JCO.2007.15.4377

C. M. Mccall, C. Shi, T. C. Cornish, D. S. Klimstra, L. H. Tang et al., Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate, The American Journal of Surgical Pathology, vol.37, issue.11, pp.1671-1677, 2013.
DOI : 10.1097/PAS.0000000000000089

H. C. Miller, P. Drymousis, R. Flora, R. Goldin, D. Spalding et al., Role of Ki-67 Proliferation Index in the Assessment of Patients with Neuroendocrine Neoplasias Regarding the Stage of Disease, World Journal of Surgery, vol.82, issue.1, pp.1353-1361, 2014.
DOI : 10.1007/s00268-014-2451-0

J. R. Won, D. Gao, C. Chow, J. Cheng, S. Y. Lau et al., A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard, Modern Pathology, vol.52, issue.11, pp.1438-1450, 2013.
DOI : 10.1093/jnci/djn326

E. A. Janssen, I. T. Øvestad, I. Skaland, H. Søiland, E. Gudlaugsson et al., LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer, Cell Oncol, vol.31, pp.335-343, 2009.

T. Ribalta, I. E. Mccutcheon, K. D. Aldape, J. M. Bruner, and G. N. Fuller, The Mitosis-Specific Antibody Anti-Phosphohistone-H3 (PHH3) Facilitates Rapid Reliable Grading of Meningiomas According to WHO 2000 Criteria, The American Journal of Surgical Pathology, vol.28, issue.11, pp.1532-1536, 2004.
DOI : 10.1097/01.pas.0000141389.06925.d5

C. Bossard, A. Jarry, C. Colombeix, K. Bach-ngohou, A. Moreau et al., Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index, Journal of Clinical Pathology, vol.59, issue.7, pp.706-710, 2006.
DOI : 10.1136/jcp.2005.030452

W. Feng, A. Malpica, I. Skaland, E. Gudlaugsson, S. J. Robboy et al., Can Proliferation Biomarkers Reliably Predict Recurrence in World Health Organization 2003 Defined Endometrial Stromal Sarcoma, Low Grade?, PLoS ONE, vol.31, issue.109, 2013.
DOI : 10.1371/journal.pone.0075899.t001

A. Alkhasawneh, J. D. Reith, T. Z. Toro, A. O. Ayed, X. Lu et al., Interobserver Variability of Mitotic Index and Utility of PHH3 for Risk Stratification in Gastrointestinal Stromal Tumors, American Journal of Clinical Pathology, vol.143, issue.3, pp.385-392, 2015.
DOI : 10.1309/AJCPAPH28VHZEKNQ

E. Duregon, A. Cassenti, A. Pittaro, L. Ventura, R. Senetta et al., Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds, Neuro-Oncology, vol.17, issue.5, pp.663-669, 2015.
DOI : 10.1093/neuonc/nov002

E. Gudlaugsson, J. Klos, I. Skaland, E. A. Janssen, R. Smaaland et al., Prognostic comparison of the proliferation markers mitotic activity index, phosphohistone H3, Ki67, steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T 1-2 N 0 M 0 breast cancer, Polish Journal of Pathology, vol.1, pp.1-8, 2013.
DOI : 10.5114/pjp.2013.34596

Y. J. Kim, R. Ketter, W. I. Steudel, and W. Feiden, Prognostic Significance of the Mitotic Index Using the Mitosis Marker Anti???Phosphohistone H3 in Meningiomas, American Journal of Clinical Pathology, vol.128, issue.1, pp.118-125, 2007.
DOI : 10.1309/HXUNAG34B3CEFDU8

A. Sun, W. Zhou, J. Lunceford, P. Strack, L. Dauffenbach et al., Level of phosphohistone H3 among various types of human cancers, BMJ Open, vol.2, issue.5, p.1071, 2012.
DOI : 10.1136/bmjopen-2012-001071